Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ovid TherapeuticsFRA:1OT -4.84%34 Debt-to-Equity is 0.06 as of Jun. 2026, which is 60% below its 10-year median of 0.15. GuruFocus rates FRA:1OT with a GF Score™ of 34/100 and a GF Value™ of €0.83. The stock has 5 warning signs investors should review. Among 956 Biotechnology companies, Ovid Therapeutics ranks better than 68.31% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Ovid Therapeutics's Debt-to-Equity or its related term are showing as below:
FRA:1OT'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.06 Med: 0.15 Max: 0.31
Current: 0.06
During the past 11 years, the highest Debt-to-Equity Ratio of Ovid Therapeutics was 0.31. The lowest was 0.06. And the median was 0.15.
FRA:1OT's Debt-to-Equity is ranked better than 68.31% of 956
companies
in the Biotechnology industry
Industry Median: 0.16
vs FRA:1OT: 0.06
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Ovid Therapeutics Debt-to-Equity Related Terms
Ovid Therapeutics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Ovid Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1OT vs ZURA, ARTV, SCTX: Debt-to-Equity Comparison
For the Biotechnology subindustry, Ovid Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ovid Therapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ovid Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Ovid Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ovid Therapeutics (FRA:1OT) has a Debt-to-Equity of 0.06 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Ovid Therapeutics and its competitors. This is 60% below median its historical median of 0.15. Over the past decade, Ovid Therapeutics' Debt-to-Equity has ranged from 0.06 to 0.31. According to the industry distribution chart, Ovid Therapeutics ranks #303 out of 956 companies in the Biotechnology industry, placing it in the top 31.7%.
Is Ovid Therapeutics' Debt-to-Equity too high?
Ovid Therapeutics' current Debt-to-Equity of 0.06 is 60% below median its 10-year median of 0.15. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 0.31. The Biotechnology industry median Debt-to-Equity is 0.16. Ovid Therapeutics' value of 0.06 is 62.5% below this industry median. Based on the distribution chart, Ovid Therapeutics ranks #303 out of 956 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ovid Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Ovid Therapeutics' Debt-to-Equity compare to ZURA and ARTV?
According to the Biotechnology industry distribution chart, Ovid Therapeutics ranks #303 out of 956 companies for Debt-to-Equity. This puts Ovid Therapeutics in the upper half of its industry. The industry median Debt-to-Equity is 0.16. Ovid Therapeutics' value of 0.06 is 62.5% below this benchmark. Historically, Ovid Therapeutics' own Debt-to-Equity has ranged from 0.06 to 0.31 over the past decade. While the company's 10-year median is 0.15 vs. the industry median of 0.16, Ovid Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ovid Therapeutics's current Debt-to-Equity of 0.06 is 62.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Ovid Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ovid Therapeutics's current Debt-to-Equity is 0.06, which is 60% below median its own 10-year median of 0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ovid Therapeutics stock overvalued right now?
Ovid Therapeutics (FRA:1OT) has a current Debt-to-Equity of 0.06. The stock's GF Value™ is €0.83, compared to a current price of €2.36 — trading 184.3% above its estimated fair value. The current Debt-to-Equity is 0.06, which is 60% below median its 10-year median of 0.15 and 62.5% below the Biotechnology industry median of 0.16. Ovid Therapeutics' overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Ovid Therapeutics (FRA:1OT), the current Debt-to-Equity is 0.06 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ovid Therapeutics (FRA:1OT) Overvalued in 2026?
Based on GuruFocus' analysis, Ovid Therapeutics stock appears to be overvalued.
The current stock price of €2.36 is trading 184.3% above its estimated GF Value™ of €0.83.
Key valuation signals for FRA:1OT:
Debt-to-Equity: 0.06 (60% below median its 10-year median of 0.15)
GF Value™: €0.83 vs. price of €2.36 (184.3% above fair value)
Industry Position: 62.5% below the Biotechnology median (#303 of 956)
No single metric tells the full story. See the FRA:1OT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
34GF Score
Get the complete analysis for FRA:1OT
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1OT has been successfully added to your 
